Seal Rock Therapeutics Announces Completion of Single Ascending Dose Cohort in Phase 1 Clinical Trial of ASK1 Inhibitor SRT-015 for NASH

Seal Rock Therapeutics, Inc. announced completion of the single ascending dose portion of its Phase I clinical trial of SRT-015, a next-generation, liver-selective inhibitor of Apoptosis Signal-regulating Kinase 1 for non-alcoholic steatohepatitis (NASH) and other liver diseases such as alcoholic hepatitis.